Advertisement
Advertisement
Trending on PharmExec
1
Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager
2
Pharma Funding Roundup: Cognito Therapeutics Closes Oversubscribed $105 Million Series C Financing, Nexcure Launches $19 Million Series A Financing
3
Teva and Blackstone Life Sciences Enter $400 Million Strategic Growth Capital Agreement
4
The Hidden Gem: Turn AI Roleplay Data into Commercial Intelligence
5